BRIEF-Merck & Co and AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China

jueves 28 de julio de 2016 02:55 GYT
 

July 28 (Reuters) - Merck & Co Inc :

* Merck and AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China

* Merck and AmoyDx plan to implement ADX-SuperARMS liquid biopsy RAS test in Chinese medical centers in 2017

* Plan to expand into other markets such as Argentina, India, Mexico, Taiwan, Hong Kong, Brazil, and Russia by 2019

* Test will be developed using AmoyDx real-time polymerase chain reaction technology,ADX-SuperARMS,will be made available in China in 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom)